Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.

View Full Paper
Ask AI
Bookmark
Share

Authors

ANAdrienne NedvedYTYun Kyoung TigerMMMuhamad Alhaj Moustafa

Discussion

Loading...

Member takes

Overview

Multicenter analysis shows predictors for cytokine release syndrome and neurotoxicity in large B cell lymphoma, indicating a need for better risk assessment.

Key Points

  • The aim was to understand risk factors for cytokine release syndrome and neurotoxicity in patients with large B cell lymphoma undergoing treatment.
  • Retrospective analysis at 21 US centers.
  • Evaluated patients receiving epcoritamab or glofitamab for large B cell lymphoma.
  • Analyzed baseline characteristics, safety, and efficacy outcomes.
  • Performed univariate analysis to identify risk factors for CRS and neurotoxicity.
  • 312 patients treated with bispecific antibodies: 193 with epcoritamab, 119 with glofitamab.
  • 39% experienced cytokine release syndrome; 25% had neurotoxicity.
  • Factors like bulky disease and elevated LDH increased risk for CRS.
  • Identified predictors for neurotoxicity and CRS, which inform management strategies.

Cite This Study

Nedved et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d74dhttps://doi.org/10.1182/blood-2025-401
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort2025
  2. 2Real-world experience with management of CRS and ICANS following CD3xCD20 bispecific antibody therapy.2026
  3. 3Risk factors for CRS and ICANS with Bispecific Antibodies for Aggressive Lymphomas2026
  4. 4Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium2025
  5. 5Impact of recent chemotherapy exposure on overall survival in patients with diffuse large B-cell lymphoma receiving bispecific antibody therapy.2026